Colin Z
Portland
LD 104

I am writing as a patient and consumer of medical cannabis to voice my strong opposition to the proposed regulatory changes that would impose excessive testing, track-and-trace mandates, and potency limits across all cannabis products.

As someone who relies on this medicine for my health and quality of life, I've experienced firsthand how effective and reliable our current medical program is. These proposed changes appear to be less about public safety and more about creating barriers for small, craft cannabis producers—those who consistently deliver high-quality, affordable, and clean medicine.

Forcing all SKUs through testing and track-and-trace may sound like good policy on paper, but in practice, it dramatically increases production costs. These costs inevitably get passed down to patients like me, making access harder and threatening the sustainability of businesses we trust. What's more, data from other states show that excessive testing does not necessarily lead to safer products. Contamination issues still persist under strict testing regimes, suggesting the problem isn't solved through more red tape.

Craft cannabis is medicine, not a commodity for large corporate monopolies to control. The more we regulate it like a pharmaceutical or industrial product, the further we get from the heart of what makes this program effective: affordable access to clean, effective, small-batch cannabis from trusted local producers.

Rather than imposing top-down restrictions that benefit large corporate interests, we should be focused on improving the current system in sustainable, patient-first ways. I urge you to reject these proposals and protect access to medical cannabis by supporting the small farms and producers who make this program work.

Thank you for your time and consideration.

Sincerely,

Colin